Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
出版年份 2022 全文链接
标题
Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-03-01
DOI
10.3389/fimmu.2022.848387
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors
- (2021) Jacinth Wing‐Sum Cheu et al. HEPATOLOGY
- Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
- (2021) Zhigang Fu et al. Hepatology International
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
- (2021) Chenhe Yi et al. HEPATOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
- (2021) Juanfang Liu et al. Frontiers in Pharmacology
- The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
- (2021) Fei Cao et al. Frontiers in Oncology
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update
- (2020) Sirish A. Kishore et al. Cancers
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm
- (2019) Shiro Miyayama et al. HEPATOLOGY RESEARCH
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
- (2019) Tim A. Labeur et al. LIVER INTERNATIONAL
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in Barcelona Clinic Liver Cancer stage C patients
- (2018) Yaohong Liu et al. ONCOLOGY RESEARCH
- Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
- (2018) Jian Zhou et al. Liver Cancer
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
- (2016) Riccardo Lencioni et al. HEPATOLOGY
- Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria
- (2016) Ron C. Gaba et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON
- (2016) Jean-François Geschwind et al. RADIOLOGY
- Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus – Eastern Hepatobiliary Surgical Hospital consensus statement
- (2016) Shuqun Cheng et al. Oncotarget
- Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Treatment with Transarterial Chemoembolization Combined with Sorafenib—A Retrospective Controlled Study
- (2014) Kangshun Zhu et al. RADIOLOGY
- Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
- (2013) Gwang Hyeon Choi et al. RADIOLOGY
- Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations
- (2011) Riccardo Lencioni et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More